| 1 |
NCT03710577 |
Completed
New |
Endocannabinoid and Psychological Responses to Yoga in Healthy Adults |
|
- Behavioral: Yoga
- Behavioral: Quiet Rest
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Plasma concentration of N-arachidonoylethanolamine
- Plasma concentration of 2-Arachidonoylglycerol (2-AG)
- Total Mood Disturbance (Profile of Mood States)
- (and 2 more...)
|
12 |
Female |
18 Years to 45 Years (Adult) |
NCT03710577 |
2017-0980 |
|
December 12, 2017 |
May 16, 2018 |
May 16, 2018 |
October 18, 2018 |
October 18, 2018 |
|
- University of Wisconsin-Madison Natatorium
Madison, Wisconsin, United States
|
|
| 2 |
NCT03708588 |
Recruiting
New |
Chewed Versus Integral Pill of Ticagrelor |
- Percutaneous Coronary Intervention
|
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Concentration of pharmacodynamics
- Number of Participants with Major adverse cardiac and cerebrovascular event MACCE
|
130 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT03708588 |
18-078_18-911 |
|
September 19, 2018 |
July 31, 2019 |
July 31, 2020 |
October 17, 2018 |
October 18, 2018 |
|
- Aurora Health Care, St. Luke's Medical Center
Milwaukee, Wisconsin, United States
|
|
| 3 |
NCT03704922 |
Recruiting
New |
Age of Blood in Sickle Cell Transfusion |
|
|
Interventional
|
Phase 2
Phase 3 |
- Blood Center of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Proportion of biochemically old red cell units
|
40 |
All |
18 Years to 45 Years (Adult) |
NCT03704922 |
00026112 |
|
October 1, 2018 |
March 30, 2021 |
March 30, 2021 |
October 15, 2018 |
October 17, 2018 |
|
- BloodCenter of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 4 |
NCT03703505 |
Completed
New |
A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348 |
|
- Drug: AG-348
- Drug: [13C6]AG-348
|
Interventional
|
Phase 1 |
- Agios Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- AG-348 Excreted Through Urine [A(eu)]
- AG-348 Excreted through Feces [A(ef)]
- Total Amount Excreted Through Urine [Cumulative A(eu)] of AG-348
- (and 20 more...)
|
8 |
Male |
18 Years to 55 Years (Adult) |
NCT03703505 |
AG348-C-009 |
|
May 24, 2018 |
June 1, 2018 |
June 4, 2018 |
October 12, 2018 |
October 12, 2018 |
|
- Covance
Madison, Wisconsin, United States
|
|
| 5 |
NCT03703492 |
Not yet recruiting
New |
Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS |
- Breast Cancer
- Ductal Carcinoma in Situ - Category
|
- Drug: (18F)FES
- Drug: Gadobenate dimeglumine
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- 18F-FES uptake in DCIS
- ER immunohistochemistry score
- Correlation of 18F-FES uptake in DCIS to ER immunohistochemistry score
- (and 7 more...)
|
34 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03703492 |
UW18063
P30CA014520
NCI-2018-02281
2018-0814 |
|
October 31, 2018 |
October 31, 2021 |
October 31, 2021 |
October 12, 2018 |
October 16, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 6 |
NCT03696758 |
Not yet recruiting
New |
Improving Right Ventricular Function in Young Adults Born Preterm |
|
- Procedure: Pulmonary Function Testing
- Procedure: Electrocardiogram
- Procedure: Cardiac Magnetic Resonance Imaging
- (and 2 more...)
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Right ventricular energetic efficiency
- left ventricular energetic efficiency
|
10 |
All |
18 Years to 35 Years (Adult) |
NCT03696758 |
2018-0796 |
|
November 2018 |
September 2020 |
September 2020 |
October 5, 2018 |
October 12, 2018 |
|
- University of Wisconsin-Madison School of Medicine and Public Health
Madison, Wisconsin, United States
|
|
| 7 |
NCT03694262 |
Not yet recruiting
New |
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) |
|
- Drug: Rucaparib
- Drug: Bevacizumab
- Drug: Atezolizumab
|
Interventional
|
Phase 2 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate
- Progression Free Survival
- Number of participants with treatment-related adverse events as assessed by CTCAE V5.0
- Overall Survival
|
30 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03694262 |
PRO |
EndoBARR |
February 1, 2019 |
February 28, 2021 |
February 28, 2026 |
October 3, 2018 |
October 3, 2018 |
|
- Froedtert Lutheran Memorial Hospital
Milwaukee, Wisconsin, United States
|
|
| 8 |
NCT03691766 |
Recruiting
New |
Photobiomodulation Therapy in Persons With Multiple Sclerosis |
- Multiple Sclerosis, Relapsing-Remitting
|
- Other: Photobiomodulation Therapy
- Other: Placebo
|
Interventional
|
Not Applicable |
- Marquette University
- University of Wisconsin, Milwaukee
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Muscle Fatigue
- Systemic Inflammation
|
30 |
All |
20 Years to 60 Years (Adult) |
NCT03691766 |
HR-1710020115 |
|
April 30, 2018 |
April 29, 2019 |
August 31, 2019 |
October 2, 2018 |
October 2, 2018 |
|
- Marquette University
Milwaukee, Wisconsin, United States
|
|
| 9 |
NCT03685461 |
Recruiting
New |
AB-Intra- and Post-Operative Measures of Auditory Function |
- Hearing Loss
- Cochlear Implant
|
- Other: Electrocochleography
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Other
|
- The CI electrode's scalar position as indicated by post-operative computed tomography (CT)
- Post-operative hearing performance
|
192 |
All |
1 Year and older (Child, Adult, Older Adult) |
NCT03685461 |
PRO00032101 |
AB-ECOG |
September 11, 2018 |
August 31, 2023 |
August 31, 2024 |
September 26, 2018 |
September 26, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 10 |
NCT03682094 |
Recruiting
New |
Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia |
|
|
Interventional
|
Early Phase 1 |
- University of Wisconsin, Madison
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Oral microbiota profiles- bacterial diversity
- Eating Assessment Test (EAT-10)
- Functional Oral Intake Scale (FOIS) Score
- (and 4 more...)
|
20 |
All |
65 Years to 99 Years (Older Adult) |
NCT03682094 |
2018-0428 |
|
August 13, 2018 |
August 31, 2019 |
August 31, 2019 |
September 24, 2018 |
September 24, 2018 |
|
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
|
| 11 |
NCT03682081 |
Recruiting
New |
Interventions for Patients With Alzheimer's Disease and Dysphagia |
|
- Device: Isometric tongue strengthening
- Drug: Biotene
|
Interventional
|
Early Phase 1 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Lingual Pressures at the Anterior and Posterior Tongue Locations
- Change in Perceived Swallow Effort
- Change in Penetration-Aspiration Scale scores
- (and 6 more...)
|
76 |
All |
18 Years to 99 Years (Adult, Older Adult) |
NCT03682081 |
2018-0835 |
|
October 1, 2018 |
September 1, 2023 |
September 1, 2023 |
September 24, 2018 |
September 24, 2018 |
|
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
|
| 12 |
NCT03675321 |
Recruiting |
Defining Adolescent Nausea Through Brain Imaging and Neurostimulation Response |
- Functional Gastrointestinal Disorders
|
- Device: Active Auricular Neurostimulation
- Device: Sham Auricular Neurostimulation
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Nausea Severity Scale
- Nausea Profile
- Baxter Retching Faces scale
|
110 |
All |
11 Years to 18 Years (Child, Adult) |
NCT03675321 |
1064187-2 |
|
April 23, 2018 |
June 2022 |
September 2022 |
September 18, 2018 |
September 18, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 13 |
NCT03675009 |
Recruiting |
Milwaukee Day Cares Indoor Air Quality Assessment and Educational Response Study |
|
- Other: Educational Programming
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
- University of Wisconsin, Milwaukee
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Health Services Research
|
- Alterations in total Volatile Organic Compounds (tVOC) temporally associated with the educational intervention
- Alterations in particulate matter (PM2.5) temporally associated with the educational intervention
- Assessment of Cleaning Practices (including VOC generation) practice changes associated with the Educational Intervention
- (and 4 more...)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT03675009 |
5520466 |
|
April 1, 2018 |
February 1, 2019 |
March 31, 2019 |
September 18, 2018 |
September 18, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 14 |
NCT03674528 |
Recruiting |
Technical Validation of MR Biomarkers of Obesity-Associated NAFLD |
- Non-Alcoholic Fatty Liver Disease
- Non-alcoholic Steatohepatitis
|
- Other: Magnetic Resonance Elastography (MRE)
- Diagnostic Test: Liver biopsy
|
Observational
|
|
- University of Wisconsin, Madison
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Optimization of MRE for 2 dimensional and 3 dimensional methods
|
145 |
All |
18 Years and older (Adult, Older Adult) |
NCT03674528 |
2018-0244
2R01DK088925-06A1 |
NAFLD |
May 4, 2018 |
May 1, 2021 |
May 1, 2023 |
September 17, 2018 |
September 17, 2018 |
|
- University of Wisconsin, Madison
Madison, Wisconsin, United States
|
|
| 15 |
NCT03656679 |
Not yet recruiting |
Paravertebral Versus Pectoralis Block for Post Mastectomy Pain |
- Pain, Postoperative
- Post-Mastectomy Chronic Pain Syndrome
- Opioid Use
|
- Procedure: Pectoralis Blockade (PECs)
- Procedure: Paravertebral Blockade
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Total Opioid Consumption
- time to perform the block
- Pain score
- (and 7 more...)
|
90 |
Female |
18 Years to 80 Years (Adult, Older Adult) |
NCT03656679 |
2018-0579
NCI-2018-01743
UW17141 |
|
October 1, 2018 |
October 1, 2020 |
December 1, 2021 |
September 3, 2018 |
September 3, 2018 |
|
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
|
| 16 |
NCT03656276 |
Recruiting |
The "ToPIC" Study = Tool to Improve Participation In Clinical Trials |
- Communication
- Physician-Patient Relations
|
- Behavioral: Tool to improve Participation In Clinical Trials (ToPIC)
|
Observational
|
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
- University of Wisconsin Institute for Clinical and Translational Research
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Number of patients that consent to a therapeutic trial.
- Number of oncologists that can learn the ToPIC tool after 3 hours of training.
- Number of patients that enroll in a therapeutic trial.
- Number of patients that agree to hear about therapeutic trial.
|
80 |
All |
19 Years and older (Adult, Older Adult) |
NCT03656276 |
UW16060
P30CA014520
2016-1579 |
|
March 10, 2017 |
July 2019 |
July 2019 |
September 3, 2018 |
September 3, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 17 |
NCT03648918 |
Recruiting |
Genetics Of Autoimmunity In Type I Diabetes |
- Type1diabetes
- Diabetes Mellitus, Type 1
- Type1 Diabetes Mellitus
- Diabetes Mellitus
|
|
Observational
|
|
- Medical College of Wisconsin
- Benaroya Research Institute
- Indiana University
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Onset of Type 1 diabetes
- Autoantibody Measurement
|
4000 |
All |
2 Years and older (Child, Adult, Older Adult) |
NCT03648918 |
142618
McGee Family Study |
|
August 2001 |
January 2050 |
January 2050 |
August 28, 2018 |
August 28, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 18 |
NCT03641989 |
Recruiting |
Correlation Between Oral Health and Systemic Inflammation (COHESION) |
- Inflammation
- Periodontal Disease
- Gingivitis
|
- Other: Plaque disclosing toothpaste
- Other: Non-plaque disclosing toothpaste
|
Interventional
|
Not Applicable |
- Marshfield Clinic Research Foundation
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Prevention
|
- Change in hsCRP levels with the use of the assigned toothpaste.
- Bleeding on Probing (BOP
- Periodontal Pocket Depth (PPD)
- (and 3 more...)
|
132 |
All |
21 Years to 84 Years (Adult, Older Adult) |
NCT03641989 |
ACH10317 |
COHESION |
September 2018 |
April 2019 |
July 2019 |
August 22, 2018 |
September 17, 2018 |
|
- Marshfield Clinic-Marshfield Center
Marshfield, Wisconsin, United States
|
|
| 19 |
NCT03641573 |
Not yet recruiting |
Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Cmax - maximum observed plasma concentration (plasma and whole blood)
- tmax - time at which Cmax occurs (plasma and whole blood)
- AUC0 t - area under the plasma concentration time curve from time zero to the last measurable concentration (plasma and whole blood)
- (and 7 more...)
|
8 |
Male |
20 Years to 60 Years (Adult) |
NCT03641573 |
ASN002AD-102 |
|
September 2018 |
December 2018 |
March 2019 |
August 22, 2018 |
August 22, 2018 |
|
- Covance Clinical Research Unit
Madison, Wisconsin, United States
|
|
| 20 |
NCT03630965 |
Recruiting |
CPR Audiovisual Tool to Impact ICU Patients' Surrogate Anxiety Level. |
|
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Measure the impact of CPR video on the Surrogate's level of anxiety during the decision-making process on code status, in the ICU compared to the control group of surrogates (No intervention group).
- Measure the impact of CPR video on patients' surrogate's knowledge about CPR, when compared to the No intervention group.
- Analyze the surrogates' comfort when watching the video.
- Describe if the CPR video's impact on surrogates' anxiety level, is affected by the patient's severity of illness as per the SOFA score.
|
30 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03630965 |
PULM-AV-CPR
PRO00029203 |
|
May 8, 2017 |
December 31, 2019 |
May 30, 2020 |
August 15, 2018 |
August 16, 2018 |
|
- Medical College of Wisconsin/Froedtert Hospital
Milwaukee, Wisconsin, United States
|
|
| 21 |
NCT03622008 |
Completed |
To Investigate the Multiple Dose Safety, Tolerability and Pharmacokinetics of WCK 4282 (FEP-TAZ) |
- Antibiotics Causing Adverse Effects in Therapeutic Use
|
- Drug: FEP-TAZ 4 g
- Other: Placebo
|
Interventional
|
Phase 1 |
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Basic Science
|
- Safety assessed by number of abnormal clinical laboratory test result
- To measure the Maximum Concentration
- To measure the Area Under the Curve [AUC]
- (and 3 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03622008 |
W-4282-105 |
|
March 23, 2018 |
May 13, 2018 |
May 30, 2018 |
August 9, 2018 |
August 10, 2018 |
|
- Spaulding Clinical Research
West Bend, Wisconsin, United States
|
|
| 22 |
NCT03621657 |
Not yet recruiting |
The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation |
- Clostridium Difficile Infection
|
- Drug: Low Dose FMT Capsule DE
- Drug: Single Dose FMT Capsule DE
- Drug: Placebo oral capsule
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Assess efficacy of oral FMT on composition and function of the gut microbiota compared to placebo.
- Comparison of treatment-related adverse events in the oral FMT regimens versus placebo.
- Determine the rate of Clostridium difficile infection (CDI) during oral FMT regimens versus placebo
- Evaluate time to Clostridium difficile infection (CDI) and/or colonization with C. difficile.
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03621657 |
2017-0789 |
GRAFT |
October 2018 |
June 1, 2019 |
June 30, 2019 |
August 8, 2018 |
October 4, 2018 |
|
- University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
|
|
| 23 |
NCT03617445 |
Not yet recruiting |
Fecal Microbiota Transplantation for C. Diff Infection in Solid Organ Transplant Recipients |
- Clostridium Difficile Infection Recurrence
|
- Drug: FMT enema
- Drug: Oral Vancomycin
- Drug: FMT enema placebo
- Drug: Oral Vancomycin placebo
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Compare the rate of recurrence of CDI in solid organ transplant recipients with FMT compared with oral vancomucin
- CDI-related QOL
- Compare the change in gut microbiota and evaluate the association between the change in gut microbiota and recurrence of CDI
- (and 2 more...)
|
158 |
All |
18 Years and older (Adult, Older Adult) |
NCT03617445 |
2018-1004 |
|
October 1, 2018 |
December 31, 2023 |
December 31, 2023 |
August 6, 2018 |
August 6, 2018 |
|
- University of Wisconsin Hospital & Clinics
Madison, Wisconsin, United States
|
|
| 24 |
NCT03617419 |
Completed |
Vscan Access R2 Feasibility Evaluation |
- Gather Feasibility Data and User Feedback on Use of a Device in Vivo on Pregnant Volunteers in Their 2nd and 3rd Trimester
|
- Device: GE VScan Access R2 Ultrasound System
- Device: GE Corometrics 170 Series Fetal Monitor
|
Interventional
|
Not Applicable |
|
Industry |
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Device Feasibility
|
- Fetal Heart Rate as measured by VScan Access R2
- Fetal Heart Rate as measured by GE Corometrics Device
- GE Voluson P8 Confirmation of Visualization of fetal heart with Yes/No answer per subject
|
16 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03617419 |
110.05-2017-GES-0001 |
|
November 14, 2017 |
November 20, 2017 |
November 20, 2017 |
August 6, 2018 |
August 8, 2018 |
|
- GE Healthcare - Milwaukee County Research Park
Wauwatosa, Wisconsin, United States
|
|
| 25 |
NCT03616795 |
Recruiting |
Study of LY3154207 in Healthy Participants |
|
- Drug: LY3154207
- Drug: [14C]-LY3154207
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Urinary Excretion of LY3154207 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered
- Fecal Excretion of LY3154207 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered
- Pharmacokinetics: Maximum Concentration (Cmax) of LY3154207
- (and 2 more...)
|
8 |
Male |
18 Years to 50 Years (Adult) |
NCT03616795 |
16303
I7S-MC-HBEE |
|
August 9, 2018 |
November 16, 2018 |
November 16, 2018 |
August 6, 2018 |
October 2, 2018 |
|
- Covance Clinical Research Inc
Madison, Wisconsin, United States
|
|
| 26 |
NCT03604783 |
Not yet recruiting |
Phase I, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors |
|
|
Interventional
|
Phase 1 |
- Tolero Pharmaceuticals, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicities (DLTs) and treatment emergent adverse events
- Determine maximum tolerated dose (MTD)
- Recommended Phase 2 Dose of TP-1287
- Determine antitumor activity of TP-1287
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03604783 |
TP-1287-101 |
|
October 2018 |
February 2021 |
May 2021 |
July 27, 2018 |
October 16, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 27 |
NCT03600350 |
Recruiting |
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer |
|
- Biological: pTVG-HP
- Drug: Nivolumab
- Drug: GM-CSF
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
- Bristol-Myers Squibb
- Madison Vaccines Inc. (MVI)
|
Other / NIH / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of subjects within acceptable toxicity boundaries
- Prostate-Specific Antigen (PSA) Complete Response (CR) Rate
- Metastasis-free Survival Rate
- (and 4 more...)
|
41 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03600350 |
UW18008
2018-0418
P30CA014520 |
|
September 10, 2018 |
October 31, 2020 |
October 31, 2022 |
July 25, 2018 |
September 18, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 28 |
NCT03598439 |
Enrolling by invitation |
Randomized Influenza Vaccine Evaluation of Immune Response |
|
- Biological: Standard IIV4
- Biological: Recombinant
- Biological: Cell-culture
|
Interventional
|
Phase 4 |
- Marshfield Clinic Research Foundation
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
|
350 |
All |
18 Years to 64 Years (Adult) |
NCT03598439 |
MCL10218 |
RIVER |
July 30, 2018 |
April 2020 |
September 2020 |
July 25, 2018 |
September 14, 2018 |
|
- Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, United States
|
|
| 29 |
NCT03596632 |
Completed |
Study Investigating a Single Oral Dose of Fenebrutinib in Healthy Volunteers |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Percentage of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) Percentage of the Total Radioactive Dose Administered Excreted from Urine and Feces"; TimeFrame: "Day 1 to end of study (approximately 35 days post-dose)
- Maximum Observed Concentration (Cmax) of Fenebrutinib and its Metabolites
- Time to Observed Maximum Concentration (Tmax) of Fenebrutinib and its Metabolites
- (and 8 more...)
|
8 |
Male |
18 Years to 60 Years (Adult) |
NCT03596632 |
GP40605 |
|
July 27, 2018 |
August 23, 2018 |
August 23, 2018 |
July 24, 2018 |
September 26, 2018 |
|
- Covance Clinical Research Unit, Inc
Madison, Wisconsin, United States
|
|
| 30 |
NCT03593694 |
Recruiting |
Technology Delivered Diabetes-Modified Behavioral Activation Treatment |
- Diabetes Mellitus, Type 2
|
- Behavioral: TECH DM-BAT
- Behavioral: TECH DMBAT Active Comparator
- Behavioral: TECH DMBAT Other
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from Baseline Hemoglobin A1c (HbA1c) at 3 and 6 months
|
150 |
All |
21 Years and older (Adult, Older Adult) |
NCT03593694 |
PRO00030535 |
TECHDMBAT |
November 6, 2017 |
December 31, 2021 |
December 31, 2021 |
July 20, 2018 |
July 20, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 31 |
NCT03591380 |
Recruiting |
CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients |
|
|
Interventional
|
Phase 1 |
- University of Wisconsin, Madison
- GlaxoSmithKline
- American College of Surgeons
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Whether belimumab added to standard of care (alemtuzumab and steroid induction with mycophenolic acid and tacrolimus maintenance immunosuppression) prevents de novo DSA with Luminex as the mean fluorescence intensity greater than zero as positive for DSA
- Determine graft survival and function by serum creatinine-eGFR and urine protein
- Report the nature, frequency, and severity of serious and non-serious adverse events greater than or equal to Grade 2 per Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0.
|
5 |
All |
18 Years to 60 Years (Adult) |
NCT03591380 |
2017-1385 |
CAMPBEL |
November 1, 2018 |
June 2020 |
June 2021 |
July 19, 2018 |
October 11, 2018 |
|
- University of Wisconsin Hospitals and Clinics
Madison, Wisconsin, United States
|
|
| 32 |
NCT03588936 |
Recruiting |
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant |
- Multiple Myeloma
- Acute Leukemia
- Chronic Leukemia
- (and 2 more...)
|
- Drug: Nivolumab
- Drug: Tocilizumab
|
Interventional
|
Phase 1 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum Tolerated Dose among Two Candidate Doses of Nivolumab in Combination with Tocilizumab
- Response Rates
- Overall Survival
- (and 2 more...)
|
12 |
All |
18 Years and older (Adult, Older Adult) |
NCT03588936 |
PRO32525 |
|
September 14, 2018 |
August 1, 2021 |
August 1, 2022 |
July 17, 2018 |
October 5, 2018 |
|
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 33 |
NCT03588884 |
Recruiting |
Repeated-dose Safety, Efficacy, PK and PD of CTAP101, IR Calcifediol, High-dose Cholecalciferol, and Paricalcitol Plus Low-dose Cholecalciferol in Patients With SHPT, CKD 3-4 and VDI |
- Secondary Hyperparathyroidism Due to Renal Causes
- Vitamin D Deficiency
- CKD Stage 3
- CKD Stage 4
|
- Drug: Calcifediol Oral Capsule
- Drug: Calcifediol Oral Product
- Drug: Cholecalciferol
- Drug: Paricalcitol Oral Capsule
|
Interventional
|
Phase 4 |
- OPKO Ireland Global Holdings Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence and Severity of Treatment-Emergent Adverse Events as assessed by CTCAE version 5.0
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03588884 |
CTAP101-CL-4001 |
|
June 8, 2018 |
November 4, 2018 |
December 4, 2018 |
July 17, 2018 |
July 17, 2018 |
|
- Spaulding Clinical Research
West Bend, Wisconsin, United States
|
|
| 34 |
NCT03582215 |
Recruiting |
Assessment of the Human Systemic Absorption of Sunscreen Ingredients |
- Systemic Exposure to Sunscreen Ingredients
|
- Drug: Sunscreen Product #1 (Cream)
- Drug: Sunscreen Product #2 (Lotion)
- Drug: Sunscreen Product #3 (Spray)
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Food and Drug Administration (FDA)
- Spaulding Clinical Research LLC
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Avobenzone maximum concentration
- Oxybenzone maximum concentration
- Octocrylene maximum concentration
- Ecamsule maximum concentration
|
48 |
All |
18 Years to 60 Years (Adult) |
NCT03582215 |
SCR-005 |
|
August 2018 |
January 2019 |
January 2020 |
July 10, 2018 |
August 20, 2018 |
|
- Spaulding Clinical Research
West Bend, Wisconsin, United States
|
|
| 35 |
NCT03575624 |
Completed |
Changing Health Behaviors to Manage Chronic Conditions in Community-dwelling African American Breast Cancer Survivors |
- Breast Cancer Female
- Survivorship
|
- Behavioral: Nutritional and goal-setting education, yoga
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in central adiposity
- Independent yoga posture series
- Change in body weight
- (and 3 more...)
|
17 |
Female |
18 Years and older (Adult, Older Adult) |
NCT03575624 |
20170126 |
|
January 26, 2017 |
June 15, 2017 |
June 15, 2017 |
July 2, 2018 |
July 2, 2018 |
|
- Mount Mary University
Milwaukee, Wisconsin, United States
|
|
| 36 |
NCT03568513 |
Recruiting |
Effect of Curcumin on Gut Microbiota in IBS |
|
- Dietary Supplement: Curcumin
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
- Clinical & Translational Science Institute of Southeast Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Alteration in Gut Microbiota
- Comparison of GI Symptoms
|
50 |
All |
10 Years to 18 Years (Child, Adult) |
NCT03568513 |
1120142
UL1TR001436 |
|
August 1, 2018 |
March 2019 |
March 2028 |
June 25, 2018 |
September 18, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 37 |
NCT03554304 |
Completed |
Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers |
- QT/QTc Interval in Healthy Volunteers
|
- Drug: WCK 5222
- Drug: IV placebo matched to WCK 5222 / Moxifloxacin IV solution
- Drug: Moxifloxacin 400-mg
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Other
|
- Incidence of delay in cardiac repolarization induced by WCK 5222
- Incidence of adverse events to assess tolerability at the supratherapeutic dose to be used in the thorough QT evaluation
- Incidence of AEs to assess the safety of high doses of single-dose administration of FEP-ZID
|
60 |
All |
18 Years to 55 Years (Adult) |
NCT03554304 |
W-5222-103 |
|
February 9, 2017 |
June 5, 2017 |
October 6, 2017 |
June 13, 2018 |
June 13, 2018 |
|
- Spaulding Clinical Research
West Bend, Wisconsin, United States
|
|
| 38 |
NCT03553472 |
Recruiting |
Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster |
- Herpes Zoster
- Inflammatory Bowel Diseases
- Crohn Disease
- Ulcerative Colitis
|
|
Observational
|
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Immune response by T cell, cell mediated immunity, to varicella zoster virus in patients with inflammatory bowel disease.
- Immune response by T cells ,cell Mediated Immunity, to varicella zoster virus in Immunosuppressed patients with IBD compared to those non-Immunosuppressed
- Immune response by T cell, cell mediated immunity, to varicella zoster virus in Immunosuppressed IBD patients compared to other immunosuppressed IBD patients
|
72 |
All |
35 Years to 49 Years (Adult) |
NCT03553472 |
2017-0512 |
|
January 1, 2018 |
December 31, 2018 |
July 31, 2019 |
June 12, 2018 |
June 12, 2018 |
|
- University of Wisconsin Digestive Health Center
Madison, Wisconsin, United States
|
|
| 39 |
NCT03552133 |
Recruiting |
Variable Dead Space Rebreathing Device to Treat Sleep Apnea |
- Sleep Apnea, Obstructive
- Sleep Apnea, Central
|
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Aim 1: Determine the effects of Smart CO2 Device on AHI
- Determine the effect of Smart C02 Device on Arousal Index
- Aim 2: Effect on Sleep state stability
- Determine the effects of Smart CO2 device on Blood pressure (both systolic and diastolic measures)
|
15 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03552133 |
2016-0475 |
|
August 2016 |
October 2019 |
October 2019 |
June 11, 2018 |
June 11, 2018 |
|
- University of Wisconsin Madison
Madison, Wisconsin, United States
|
|
| 40 |
NCT03542578 |
Recruiting |
Diagnosis of Fatty Liver With Outpatient Ultrasound |
|
- Device: outpatient evaluation of fatty liver
|
Observational
|
|
- Medical College of Wisconsin
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Outpatient ultrasound in diagnosis of fatty liver diagnosis
|
500 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03542578 |
PRO00029401 |
|
September 12, 2018 |
June 30, 2023 |
June 30, 2023 |
May 31, 2018 |
September 13, 2018 |
|
- Froedtert Hospital
Milwaukee, Wisconsin, United States
|
|
| 41 |
NCT03539978 |
Recruiting |
Peds SM-THINk: Nursing Interventions to Improve Discharge Outcomes |
|
|
Observational
|
|
- Medical College of Wisconsin
- Clinical & Translational Science Institute
- Marquette University
- (and 2 more...)
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Improved parent experience
|
1800 |
All |
up to 100 Years (Child, Adult, Older Adult) |
NCT03539978 |
1118599 |
SM-THINk |
August 30, 2018 |
March 31, 2019 |
April 30, 2020 |
May 30, 2018 |
October 4, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 42 |
NCT03527537 |
Not yet recruiting |
Threshold for Initiation of Medical Treatment for Women With Gestational Diabetes |
|
- Drug: Insulin
- Drug: Glyburide
- Drug: Metformin
|
Interventional
|
Phase 4 |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Composite Neonatal Outcome
- Cesarean Delivery Rate
|
284 |
Female |
18 Years to 45 Years (Adult) |
NCT03527537 |
PRO00030802 |
TIME |
August 1, 2018 |
June 1, 2021 |
June 1, 2028 |
May 17, 2018 |
May 17, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 43 |
NCT03526458 |
Enrolling by invitation |
Clinical Trial Evaluating the Efficiency of Holmium Laser Settings on Urinary Stones |
- Stone Ureter
- Stone;Renal
- Surgery
|
- Device: Holmium:YAG laser
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
|
48 |
All |
18 Years and older (Adult, Older Adult) |
NCT03526458 |
2017-0252 |
|
October 1, 2018 |
October 23, 2022 |
October 23, 2022 |
May 16, 2018 |
September 28, 2018 |
|
- University of Wisconsin
Madison, Wisconsin, United States
|
|
| 44 |
NCT03525405 |
Completed |
A Study to Evaluate the Mass Balance of 14C-Napabucasin in Healthy Adult Male Subjects |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Pharmacokinetics for napabucasin and metabolites by assessing plasma concentration
- Pharmacokinetics for napabucasin and metabolites by assessing urinary concentration
- Pharmacokinetics for napabucasin and metabolites by assessing fecal concentration
- Number of Patients with Adverse Events
|
8 |
Male |
18 Years to 45 Years (Adult) |
NCT03525405 |
BBI608-104 |
|
May 18, 2018 |
June 2, 2018 |
June 2, 2018 |
May 15, 2018 |
September 18, 2018 |
|
- Covance Clinical Research Unit
Madison, Wisconsin, United States
|
|
| 45 |
NCT03523663 |
Recruiting |
System for Determining Ideal Drug Doses for ADHD - Stages 1 and 2 |
- Attention Deficit Hyperactivity Disorder
|
- Other: no intervention. measure eye movement data
|
Observational
|
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Task choice
- Reaction time
- Eye position
|
45 |
All |
8 Years to 12 Years (Child) |
NCT03523663 |
2015-0857 |
|
January 2016 |
June 2019 |
June 2019 |
May 14, 2018 |
May 18, 2018 |
|
- Wisconsin Institutes of Medical Research
Madison, Wisconsin, United States
|
|
| 46 |
NCT03522077 |
Recruiting |
RAVE: Radial Artery Vascular Complication and Resource Utilization |
- Angiogram
- Percutaneous Coronary Intervention
|
- Device: SoftSeal®-STF hemostatic pad
- Device: VascBand™ Hemostat
|
Interventional
|
Phase 4 |
- Aurora Health Care
- Chitogen, Inc.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Rate of acute radial artery occlusion
- Time to hemostasis
- Time to discharge
- (and 9 more...)
|
766 |
All |
18 Years and older (Adult, Older Adult) |
NCT03522077 |
17-132 |
|
May 9, 2018 |
December 1, 2019 |
December 1, 2019 |
May 11, 2018 |
October 8, 2018 |
|
- Aurora Health Care
Milwaukee, Wisconsin, United States
|
|
| 47 |
NCT03520010 |
Recruiting |
Facilitated Implementation of Antibiotic Stewardship in Wisconsin Nursing Homes |
- UTI - Urinary Tract Infection
|
- Behavioral: Externally-facilitated implementation
- Behavioral: Internally-driven implementation
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Urine culture orders per 1,000 resident-days
- Antibiotic starts for treatment of suspected UTI per 1,000 resident-days
- Days of therapy for treatment of suspected UTI per 1,000 resident-days
- (and 7 more...)
|
420 |
All |
18 Years and older (Adult, Older Adult) |
NCT03520010 |
2018-0125 |
IMUNIFI |
June 1, 2018 |
March 31, 2020 |
August 31, 2020 |
May 9, 2018 |
October 16, 2018 |
|
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
|
| 48 |
NCT03513757 |
Recruiting |
Dexmedetomidine and Propofol for Pediatric MRI Sedation |
- Headache
- Tumor
- Seizure Disorder
- (and 4 more...)
|
- Drug: propofol
- Drug: Dexmedetomidine
|
Interventional
|
Phase 4 |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficiency of propofol dexmedetomidine sedation compared with propofol infusion
- total propofol administration
- dexmedetomidine dose
- (and 10 more...)
|
70 |
All |
12 Months to 60 Months (Child) |
NCT03513757 |
CHW 959242-5 |
|
March 4, 2018 |
December 31, 2018 |
December 31, 2018 |
May 2, 2018 |
May 3, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 49 |
NCT03511157 |
Active, not recruiting |
Ischemic Preconditioning Claudication Study |
- Intermittent Claudication
- Ischemia Vascular
- Peripheral Arterial Disease
- Peripheral Vascular Disease
|
- Other: Ischemic Preconditioning
- Other: Control Group
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Peak walking time
- Muscle Fatigue
- Claudication onset time
|
24 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03511157 |
PRO00031772 |
|
June 14, 2018 |
June 19, 2019 |
August 19, 2019 |
April 27, 2018 |
October 2, 2018 |
|
- Froedtert and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 50 |
NCT03500081 |
Recruiting |
Solid Tumor Imaging MR‐Linac (STIM Study) |
|
|
Observational
|
|
- Medical College of Wisconsin
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Determine the optimal set of scan parameters (e.g., field of view).
|
240 |
All |
18 Years and older (Adult, Older Adult) |
NCT03500081 |
PRO 30440 |
|
October 2, 2017 |
May 10, 2019 |
July 1, 2021 |
April 17, 2018 |
April 17, 2018 |
|
- Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 51 |
NCT03490292 |
Suspended |
Avelumab With Chemoradiation for Stage II/III Resectable Esophageal Cancer |
- Resectable Esophageal Cancer
|
- Combination Product: Avelumab combined with Chemoradiation
- Drug: Carboplatin
- Drug: Paclitaxel
- Radiation: Radiation
|
Interventional
|
Phase 1
Phase 2 |
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Part 1: Dose Limiting Toxicity.
- Part 2: Pathological complete response rate.
- Number of Adverse Events.
- (and 4 more...)
|
24 |
All |
18 Years and older (Adult, Older Adult) |
NCT03490292 |
UW17106
P30CA014520
NCI-2018-00150
2017-1491 |
|
June 8, 2018 |
February 2021 |
February 2024 |
April 6, 2018 |
October 9, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 52 |
NCT03488875 |
Recruiting |
Impact of Mindfulness Training on Stress-related Health Outcomes in Law Enforcement |
- Stress, Psychological
- Sleep
- Inflammation
- Mental Health
|
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
- U.S. Department of Justice
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Change in perceived occupational stress
- Change in diurnal cortisol slope
- Change in cortisol awakening response
- (and 3 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03488875 |
2017-1529
2017-R2-CX-0033 |
|
March 6, 2018 |
December 31, 2020 |
December 31, 2020 |
April 5, 2018 |
April 12, 2018 |
|
- Center for Healthy Minds, University of Wisconsin-Madison
Madison, Wisconsin, United States
|
|
| 53 |
NCT03482726 |
Enrolling by invitation |
Cadence Modulation in Cyclists |
|
- Behavioral: Cycling Cadence Modulation
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Time to exhaustion T(max)
- Ventilatory threshold (VT)
- Maximal cardiac output
- (and 9 more...)
|
40 |
All |
18 Years to 89 Years (Adult, Older Adult) |
NCT03482726 |
2017-0131 |
|
June 26, 2017 |
June 25, 2019 |
December 31, 2020 |
March 29, 2018 |
March 29, 2018 |
|
- University of Wisconsin
Madison, Wisconsin, United States
|
|
| 54 |
NCT03480451 |
Recruiting |
Targeted Intervention for Patient Centered Outcome in Patients With Idiopathic Pulmonary Fibrosis |
- Idiopathic Pulmonary Fibrosis
|
- Other: Multi-Disciplinary Patient Centered Rehab and Education
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Assess the change in coping skills for patients with IPF before and after a comprehensive pulmonary rehabilitation program.
- Assess the change in quality of life for patients with IPF before and after a comprehensive pulmonary rehabilitation program.
- Assess the change in depression, anxiety for patients with IPF before and after a comprehensive pulmonary rehabilitation program.
|
30 |
All |
18 Years and older (Adult, Older Adult) |
NCT03480451 |
28280 |
IPF |
September 12, 2017 |
December 2018 |
December 2019 |
March 29, 2018 |
March 29, 2018 |
|
- Froedtert Memorial Lutheran Hospital
Milwaukee, Wisconsin, United States
|
|
| 55 |
NCT03478462 |
Not yet recruiting |
Dose Escalation Study of CLR 131 in Children and Adolescents With Relapsed or Refractory Malignant Brain Cancer, Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma |
- Pediatric Solid Tumor
- Pediatric Lymphoma
- Pediatric Brain Tumor
|
|
Interventional
|
Phase 1 |
- Cellectar Biosciences, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of participants with dose limiting toxicities (DLT)
- Determination of therapeutic activity of CLR 131 in children and adolescents
|
30 |
All |
2 Years to 21 Years (Child, Adult) |
NCT03478462 |
DCL-17-001 |
|
July 2018 |
September 2020 |
December 2020 |
March 27, 2018 |
March 27, 2018 |
|
- University of Wisconsin Hospital and Clinics
Madison, Wisconsin, United States
|
|
| 56 |
NCT03463395 |
Recruiting |
Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux |
|
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Tissue and Salivary Pepsin Levels
|
60 |
All |
18 Years and older (Adult, Older Adult) |
NCT03463395 |
PRO30948 |
|
August 2018 |
November 2019 |
November 2019 |
March 13, 2018 |
August 21, 2018 |
|
- Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 57 |
NCT03462459 |
Recruiting |
Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection |
- Recurrent Clostridium Difficile Infection
- Clostridium Difficile Infection
|
- Drug: Vancomycin
- Drug: Placebo
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- Indiana University
- Medical College of Wisconsin
- Agency for Healthcare Research and Quality (AHRQ)
|
Other / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Recurrent Clostridium difficile infection (CDI)
- Gut microbiome composition
- Vancomycin-resistant enterococcus (VRE) colonization in patients receiving vancomycin vs. placebo
- Determine whether Clostridium difficile positivity on any stool sample is a predictor of CDI recurrence.
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT03462459 |
2017-0927
1R01HS025713-01 |
|
May 21, 2018 |
December 31, 2021 |
December 31, 2021 |
March 12, 2018 |
June 20, 2018 |
|
- University of Wisconsin-Madison
Madison, Wisconsin, United States
|
|
| 58 |
NCT03461861 |
Recruiting |
Network-Level Mechanisms for Preclinical Alzheimer's Disease Development |
|
- Drug: Levetiracetam 250 mg
- Other: Placebo
|
Interventional
|
Phase 2 |
- Medical College of Wisconsin
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Functional connectivity strengths of neural networks
- Rey Auditory Verbal Learning Test (AVLT)
- Logical memory test (LMT)
|
50 |
All |
55 Years to 75 Years (Adult, Older Adult) |
NCT03461861 |
PRO00031146
R21AG056882-01 |
|
November 2018 |
March 31, 2019 |
March 31, 2019 |
March 12, 2018 |
October 5, 2018 |
|
- Froedtert & The Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 59 |
NCT03459729 |
Not yet recruiting |
Antitumor B KAC-α PK Study |
- Squamous Cell Carcinoma of the Oral Cavity
|
- Dietary Supplement: Antitumor B KAC-α
|
Interventional
|
Early Phase 1 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Antitumor B KAC-α in blood samples.
- Antitumor B KAC-α in saliva.
- Antitumor B KAC-α accumulation in tumor tissue specimen.
|
8 |
All |
18 Years and older (Adult, Older Adult) |
NCT03459729 |
IIT-WONG-ATB |
|
April 1, 2018 |
May 1, 2019 |
May 1, 2020 |
March 9, 2018 |
March 9, 2018 |
|
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 60 |
NCT03455218 |
Recruiting |
Nitric Oxide Administration During Pediatric Cardiopulmonary Bypass Surgery to Prevent Platelet Activation |
- Inflammation
- Platelet Dysfunction
|
- Drug: Nitric Oxide
- Drug: Placebo
- Device: INOmax
|
Interventional
|
Phase 2
Phase 3 |
- Medical College of Wisconsin
- Mallinckrodt
- Clinical & Translational Science Institute of Southeast Wisconsin
- Blood Center of Wisconsin
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Platelet Count
- 30 day mortality
- Hospital length of stay
- (and 15 more...)
|
40 |
All |
up to 1 Year (Child) |
NCT03455218 |
1111115-1NO in CPB 001 |
|
April 25, 2018 |
March 30, 2019 |
June 30, 2019 |
March 6, 2018 |
April 27, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 61 |
NCT03448172 |
Completed |
Single-dose Study of [14C]PF-05221304 Metabolism and Excretion in Healthy Adult Male Subjects |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Mass Balance
- Metabolic profiling for PF-05221304 in plasma, urine, and feces
- Radioactivity AUClast
- (and 10 more...)
|
6 |
Male |
18 Years to 45 Years (Adult) |
NCT03448172 |
C1171010 |
|
April 18, 2018 |
May 26, 2018 |
June 13, 2018 |
February 27, 2018 |
October 5, 2018 |
|
- Covance Clinical Research Unit Inc.
Madison, Wisconsin, United States
|
|
| 62 |
NCT03445169 |
Not yet recruiting |
A Food Effect Study in Healthy Volunteers With PT2977 Tablets |
|
|
Interventional
|
Phase 1 |
- Peloton Therapeutics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Plasma Concentrations of PT2977 assessed in both the fasting and non-fasting conditions and compared
|
16 |
All |
18 Years to 45 Years (Adult) |
NCT03445169 |
PT2977-103 |
|
March 2018 |
May 2018 |
September 2018 |
February 26, 2018 |
February 27, 2018 |
|
- Spaulding Clinical
West Bend, Wisconsin, United States
|
|
| 63 |
NCT03443180 |
Recruiting |
Gluten and Amylase Trypsin Inhibitors (ATI) Free Diet |
|
- Other: Gluten and Amylase Trypsin Inhibitors (ATI)-free diet
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in the plasma-induced transcriptional assay
- Stool microbial composition
- Plasma microbial antigen detection
- Leukocyte analyses
|
50 |
All |
5 Years to 17 Years (Child) |
NCT03443180 |
1138159 |
|
January 1, 2018 |
December 31, 2020 |
December 31, 2020 |
February 23, 2018 |
September 25, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 64 |
NCT03441048 |
Recruiting |
Lintuzumab-Ac225 in Combination With CLAG-M Chemotherapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
|
- Drug: Lintuzumab AC 225
- Drug: Cladribine
- Drug: Cytarabine
- (and 2 more...)
|
Interventional
|
Phase 1 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-Tolerated Dose of Lintuzumab-AC225
- Toxicities of the Combination
- Response Rates
- (and 2 more...)
|
18 |
All |
18 Years and older (Adult, Older Adult) |
NCT03441048 |
ABEDIN-IIT |
|
May 22, 2018 |
April 1, 2019 |
April 1, 2020 |
February 21, 2018 |
May 24, 2018 |
|
- Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 65 |
NCT03434652 |
Recruiting |
Auricular Neurostimulation for Cyclic Vomiting Syndrome |
- Cyclic Vomiting Syndrome
- Abdominal Migraine
|
- Device: Percutaneous neurostimulation
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Baxter Retching Faces Scale
- Numeric pain scale
- Anxiety
- (and 4 more...)
|
50 |
All |
10 Years to 65 Years (Child, Adult, Older Adult) |
NCT03434652 |
1102505-4 |
|
January 31, 2018 |
June 30, 2019 |
December 31, 2019 |
February 15, 2018 |
September 19, 2018 |
|
- Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 66 |
NCT03423862 |
Recruiting |
Development of Predictive Biomarkers |
|
- Other: Mixed Meal Tolerance Test
|
Observational
|
|
- Medical College of Wisconsin
- Juvenile Diabetes Research Foundation
- Benaroya Research Institute
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Predicting the honeymoon period
- Establishing the relationship between baseline inflammation and other measures
|
100 |
All |
6 Years to 17 Years (Child) |
NCT03423862 |
1048169 |
|
October 1, 2017 |
September 30, 2020 |
September 30, 2020 |
February 6, 2018 |
February 7, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 67 |
NCT03423589 |
Enrolling by invitation |
Modulation of Type 1 Diabetes Susceptibility Through the Use of Probiotics |
- Type1diabetes
- Type1 Diabetes Mellitus
|
- Dietary Supplement: VSL#3
|
Interventional
|
Not Applicable |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Alterations in Plasma-Induced Transcriptional Analysis
- Intestinal Microbiota
|
30 |
All |
5 Years to 17 Years (Child) |
NCT03423589 |
1171017 |
|
April 23, 2018 |
December 31, 2018 |
December 31, 2018 |
February 6, 2018 |
May 28, 2018 |
|
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 68 |
NCT03417076 |
Withdrawn |
Absolute Bioavailability Study With Bexagliflozin |
|
|
Interventional
|
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- absolute bioavailability (Fp.o.) of bexagliflozin tablets
- adverse events
|
0 |
Male |
18 Years to 55 Years (Adult) |
NCT03417076 |
THR-1442-C-446 |
|
August 1, 2018 |
September 16, 2018 |
September 16, 2018 |
January 31, 2018 |
June 25, 2018 |
|
- Clinical Research Site
Madison, Wisconsin, United States
|
|
| 69 |
NCT03412084 |
Recruiting |
A "Stand Up and Move More" Intervention for Older Adults |
|
- Behavioral: Stand up and move more
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
- National Institute on Aging (NIA)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction in Sedentary behavior (i.e., total sitting time per day)
- Short physical performance battery
|
80 |
All |
56 Years and older (Adult, Older Adult) |
NCT03412084 |
2013-1155
R21AG054916 |
|
March 14, 2018 |
August 2019 |
August 2019 |
January 26, 2018 |
March 21, 2018 |
|
- Kelli Koltyn
Madison, Wisconsin, United States
|
|
| 70 |
NCT03406923 |
Not yet recruiting |
Self-efficacy, Beliefs and Adherence- Pilot and Feasibility Trial of a Pharmacist-led Intervention |
|
- Other: Health literacy-psychosocial support
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
- Merck Sharp & Dohme Corp.
- William S. Middleton Memorial Veterans Hospital
|
Other / Industry / U.S. Fed |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Health Services Research
|
- Change in diabetes medication adherence
- Change in diabetes control
- Self-efficacy for medication use
- (and 4 more...)
|
50 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03406923 |
2017-0951 |
|
November 1, 2018 |
December 31, 2020 |
December 31, 2020 |
January 23, 2018 |
October 10, 2018 |
|
- William S. Middleton Memorial Veterans Hospital
Madison, Wisconsin, United States
|
|
| 71 |
NCT03404804 |
Recruiting |
Oral Challenge in the Pediatric ED |
- Penicillin Allergy
- Pediatric Emergency Medicine
|
|
Interventional
|
Phase 4 |
- Medical College of Wisconsin
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Oral amoxicillin challenge
- Oral amoxicillin challenge follow-up
- Cost analysis
|
100 |
All |
3 Years to 16 Years (Child) |
NCT03404804 |
1069530-3 |
OPEN |
December 4, 2017 |
December 4, 2018 |
December 4, 2018 |
January 19, 2018 |
January 19, 2018 |
|
- David Vyles
Milwaukee, Wisconsin, United States
|
|
| 72 |
NCT03393741 |
Suspended |
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy |
- Breast Cancer
- Breast Neoplasms
|
- Drug: Taxane
- Drug: Vinorelbine
- Drug: Ixabepilone
- (and 2 more...)
|
Observational
|
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Feasibility of measuring biomarkers in advanced breast tumors at 20 +/- 2 hours after chemotherapy
- Measure intratumoral drug levels at 20 +/- 2 hours after chemotherapy
- Measure serum drug levels at 20 +/- 2 hours after chemotherapy
- (and 7 more...)
|
35 |
All |
18 Years and older (Adult, Older Adult) |
NCT03393741 |
UW16151
P30CA014520
NCI-2017-01614
2017-0668 |
|
January 29, 2018 |
February 28, 2019 |
February 28, 2019 |
January 8, 2018 |
October 16, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 73 |
NCT03387735 |
Recruiting |
Multiple Chronic Conditions for Older Adults |
|
- Other: Treatment as usual (TAU) + Internet
- Behavioral: TAU + C-CHESS
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
- University of Wisconsin Hospital and Clinics (UW Health)
- Medical University of South Carolina
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Health outcomes
- Healthcare use
- Chronic condition outcome: Hypertension
- (and 3 more...)
|
330 |
All |
65 Years and older (Older Adult) |
NCT03387735 |
2017-0849 |
|
January 1, 2018 |
June 2021 |
June 2021 |
January 2, 2018 |
February 20, 2018 |
|
- UW Health Clinics
Madison, Wisconsin, United States
|
|
| 74 |
NCT03387514 |
Recruiting |
Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies |
|
- Drug: PSMA-based 18F-DCFPyL PET tracer for PET/CT exams
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- RECIST 1.1 Based Criteria
- HIstopathological Endpoints
- Measure therapy response of patient specific uVESSEL (a micro scale organotypic co-culture model)
- Evaluate the predictive power and validate the uVESSEL model
|
15 |
All |
18 Years and older (Adult, Older Adult) |
NCT03387514 |
2017-1343
P30CA014520 |
UW17104 |
June 8, 2018 |
January 15, 2021 |
January 15, 2022 |
January 2, 2018 |
October 10, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 75 |
NCT03384173 |
Recruiting |
NIRS for AKI in Preterm Infants |
- Acute Kidney Injury
- Premature Infant
|
- Device: Near Infrared Spectroscopy
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Renal NIRS tissue oxygenation differential
- Correlation of renal NIRS values to serum creatinine and urine output
- Effect of neonatal medications on renal NIRS values
|
60 |
All |
up to 7 Days (Child) |
NCT03384173 |
2017-0589
207-013 |
nNIRS-AKI |
April 25, 2018 |
December 31, 2018 |
December 31, 2018 |
December 27, 2017 |
October 17, 2018 |
|
- UnityPoint Health Meriter Hospital
Madison, Wisconsin, United States
|
|
| 76 |
NCT03381339 |
Recruiting |
Powertoothbrushing for Treating Gingivitis |
- Gingivitis, Treatment, Oral Hygiene
|
- Device: Oscillating rotating power toothbrush
|
Interventional
|
Not Applicable |
- Marquette University
- Sunstar, Inc.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Reduction in Gingivitis
- Single use reduction in overnight plaque
- Reduction in overnight plaque formation
|
70 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03381339 |
MarquetteU |
|
December 5, 2017 |
June 25, 2018 |
June 25, 2018 |
December 22, 2017 |
December 22, 2017 |
|
- Marquette University School of Dentistry
Milwaukee, Wisconsin, United States
|
|
| 77 |
NCT03378505 |
Active, not recruiting |
Impact of Mobile App on Purpose and Well-Being Among College Students |
|
- Behavioral: Mobile App
- Behavioral: Reflection
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Change in Health Behaviors
- Change in Resiliency
- Change in Self-Regulation
- (and 3 more...)
|
120 |
All |
18 Years and older (Adult, Older Adult) |
NCT03378505 |
2017-1371 |
PWB |
January 24, 2018 |
May 2018 |
January 2019 |
December 19, 2017 |
March 8, 2018 |
|
- School of Human Ecology
Madison, Wisconsin, United States
|
|
| 78 |
NCT03375892 |
Recruiting |
A Phase II Study of the Use of Deep Inspiration Breath Hold and Prone Irradiation to Decrease Cardiac Radiation Exposure |
- Breast Cancer
- Ductal Carcinoma in Situ
- Invasive Breast Cancer
|
- Other: Deep Inspiration Breath Hold and Free-breathing
|
Interventional
|
Phase 2 |
- Medical College of Wisconsin
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determination of a radiation technique for patients treated for left-sided breast cancer that minimizes exposure to the heart, as measured by the mean heart dose.
- Changes in EKG readings prior to, during or after radiation therapy.
- Changes in echocardiogram parameters prior to, during or after radiation therapy.
- Change in mitochondrial energy production, as measured in leukocytes (peripheral blood mononuclear cells) from patients prior to and after undergoing radiation therapy.
|
45 |
All |
18 Years and older (Adult, Older Adult) |
NCT03375892 |
IIT-Bergom |
|
March 3, 2018 |
June 30, 2019 |
June 30, 2020 |
December 18, 2017 |
April 12, 2018 |
|
- Froedtert Hospital and Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 79 |
NCT03375619 |
Recruiting |
Long-term Follow-up Study of Patients Receiving CAR-20/19-T Cells |
- CLL/SLL
- Lymphomas Non-Hodgkin's B-Cell
|
- Other: Long-Term Follow-Up of Patients who Received CAR-20/19-T cells
|
Observational
|
|
- Medical College of Wisconsin
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Proportion of patients with listed categories: new malignancies, new incidence or exacerbation of a prior rheumatologic or other autoimmune disorder, new incidence of a hematologic disorder.
- Proportion of patients who relapse or progress among patients who had not relapsed or progressed at study entry from CAR-20/19 T cell treatment; Incidence of death.
- Absolute B- and T-lymphocyte counts.
- (and 2 more...)
|
24 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03375619 |
PRO30317 |
|
December 1, 2017 |
August 1, 2020 |
August 1, 2040 |
December 18, 2017 |
March 23, 2018 |
|
- Froedtert Hospital & Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 80 |
NCT03369054 |
Recruiting |
Psychotherapy Trial With Transgender Clients |
- Transgender Persons, M01.777.500
|
- Behavioral: Minority Stress Treatment
- Behavioral: Treatment As usual
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Measuring Weekly Change in the Outcome Questionnaire 45; Lambert et al., 2013
- Measuring 3 month and 9 month Change in the Outcome Questionnaire 45; Lambert et al., 2013
- Measuring 3 month and 9 month Change in the World Health Organization WHOQOL-BREF Quality of Life Assessment (WHOQOL-BREF); Power, 1998
|
20 |
All |
18 Years and older (Adult, Older Adult) |
NCT03369054 |
2017-0816 |
|
December 1, 2017 |
August 2018 |
August 2018 |
December 11, 2017 |
May 2, 2018 |
|
- University of Wisconsin Madison
Madison, Wisconsin, United States
|
|
| 81 |
NCT03363659 |
Recruiting |
Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma Multiforme |
- Glioblastoma
- Glioblastoma Multiforme
|
- Drug: Disulfiram
- Dietary Supplement: Copper gluconate
- Drug: Temozolomide
|
Interventional
|
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective Response Rate
- Six months progression-free survival
- Toxicity
- (and 2 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03363659 |
17.56 |
|
March 28, 2018 |
January 21, 2026 |
January 21, 2027 |
December 6, 2017 |
August 15, 2018 |
|
- Aurora Health Care, Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States
|
|
| 82 |
NCT03358563 |
Recruiting |
Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer |
|
- Drug: Docetaxel
- Drug: Degarelix
- Drug: Bicalutamide
|
Interventional
|
Early Phase 1 |
- University of Wisconsin, Madison
- United States Department of Defense
- National Cancer Institute (NCI)
|
Other / U.S. Fed / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in pCR rates
- Change in PSA
- PSA Recurrence
- Safety and tolerability of combination ADT and docetaxel measured by CTCAE v.4.0
|
30 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03358563 |
UW17009
P30CA014520
2017-0606 |
|
January 5, 2018 |
January 2019 |
January 2020 |
November 30, 2017 |
May 17, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 83 |
NCT03356470 |
Enrolling by invitation |
Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma |
|
|
Observational
|
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Correlation of baseline of response and antitumor response
- Correlation of in vivo clonally amplified T cells to FDG PET uptake in melanoma tumors
- To correlate histologic and molecular markers of antitumor response to FLT PET uptake in melanoma tumors following treatment with anti-PD-1
|
4 |
All |
18 Years and older (Adult, Older Adult) |
NCT03356470 |
UW16032
2017-0046
P30CA014520 |
|
November 2, 2017 |
December 2018 |
December 2018 |
November 29, 2017 |
December 12, 2017 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 84 |
NCT03352908 |
Recruiting |
Yale Swallow Protocol in Extubated Patients |
|
|
Observational
|
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Determine the sensitivity of the Yale Swallow Protocol (YSP) through aspiration identification in recently extubated patients.
|
188 |
All |
18 Years and older (Adult, Older Adult) |
NCT03352908 |
2016-1149 |
|
October 25, 2017 |
August 13, 2019 |
August 13, 2019 |
November 24, 2017 |
October 3, 2018 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
|
| 85 |
NCT03349125 |
Completed |
Study: C-Collar and Dysphagia |
|
- Behavioral: Collar On
- Behavioral: Collar Off
|
Observational
|
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- To identify aspiration between study conditions (with and without a collar).
|
23 |
All |
60 Years and older (Adult, Older Adult) |
NCT03349125 |
2017-0222 |
|
September 17, 2013 |
May 17, 2017 |
April 5, 2018 |
November 21, 2017 |
October 3, 2018 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
|
| 86 |
NCT03349112 |
Active, not recruiting |
Study: Manometry With & Without Lidocaine |
|
- Behavioral: 4% Lidocaine Spray
- Behavioral: 2% Viscous Lidocaine
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- A quantifiable difference of perceived comfort reduction during HRPM with or without lidocaine as assessed through analysis of a visual analog scale.
|
36 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03349112 |
2015-0485 |
|
December 22, 2015 |
December 2020 |
December 2020 |
November 21, 2017 |
July 6, 2018 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
|
| 87 |
NCT03349086 |
Active, not recruiting |
Effects of Vocal Exercises for Spasmodic Dysphonia |
- Adductor Spasmodic Dysphonia
|
- Behavioral: Voice Exercise
|
Interventional
|
Not Applicable |
- University of Wisconsin, Madison
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- A quantifiable difference between the effects of voice exercise vs. voice rest post Adductor Spasmodic Dysphonia botox treatment through analysis of the Voice Handicap Index Questionnaire.
|
40 |
Female |
21 Years to 70 Years (Adult, Older Adult) |
NCT03349086 |
2013-1746 |
|
July 28, 2014 |
October 15, 2018 |
October 15, 2018 |
November 21, 2017 |
October 3, 2018 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
|
| 88 |
NCT03342378 |
Recruiting |
PET-MRI Assessment of Early Tumor Response to Predict Outcomes of HPV-Positive Oropharynx Cancer Patients |
- Squamous Cell Carcinoma
- Oropharynx Cancer
|
- Radiation: Intensity modulated radiotherapy (IMRT)
- Drug: Chemotherapy
- Diagnostic Test: PET-MRI
|
Observational
|
|
- University of Wisconsin, Madison
- National Cancer Institute (NCI)
- National Institute of Dental and Craniofacial Research (NIDCR)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To determine if the primary tumor response in patients with IR HPV-positive
- To define the difference of the primary tumor response in patients with LR HPV-positive OPSCC and HPV-negative OPSCC following 2 weeks of CRT.
|
58 |
All |
18 Years and older (Adult, Older Adult) |
NCT03342378 |
UW17078
P30CA014520
2017-1010
P50DE026787 |
|
May 3, 2018 |
October 2020 |
October 2022 |
November 17, 2017 |
June 27, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 89 |
NCT03342157 |
Recruiting |
Docusate/Senna for the Treatment of Diabetic Gastroparesis |
|
|
Interventional
|
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD)
- Frequency of use of breakthrough medication
- Frequency of bowel movements
|
60 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03342157 |
17.120 |
|
April 2, 2018 |
January 25, 2019 |
January 25, 2019 |
November 14, 2017 |
April 4, 2018 |
|
- Aurora Health Care
Milwaukee, Wisconsin, United States
|
|
| 90 |
NCT03336125 |
Enrolling by invitation |
Key Nutrients and Mental Health |
|
- Dietary Supplement: Vitamin D
- Dietary Supplement: Placebo
|
Interventional
|
Not Applicable |
- University of Bergen
- Wisconsin Department of Health and Family Services
- Haukeland University Hospital
- National Institute of Nutrition and Seafood Research, Norway
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- Change in vitamin D level in blood from pre-test (baseline) to post-test (after 4 months)
- Change in serotonin from pre-test (baseline) to post-test (after 4 months)
- Change in total cholesterol from pre-test (baseline) to post-test (after 4 months)
- (and 15 more...)
|
100 |
Male |
18 Years and older (Adult, Older Adult) |
NCT03336125 |
983 974 724 |
|
November 2017 |
May 2018 |
May 2018 |
November 8, 2017 |
November 8, 2017 |
|
- Sand Ridge Secure Treatment Center
Mauston, Wisconsin, United States
|
|
| 91 |
NCT03328520 |
Completed |
WILD 5 Wellness, A 30-Day Intervention |
- Anxiety
- Depression
- Cognitive Functioning
- Wellness
|
- Behavioral: WILD 5 Wellness Intervention
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Change in Patient Health Questionnaire-9 (PHQ-9)
- Change in Generalized Anxiety Disorder-7 (GAD-7)
- Change in the HERO Wellness Scale
- (and 3 more...)
|
33 |
All |
17 Years and older (Child, Adult, Older Adult) |
NCT03328520 |
374 |
|
October 24, 2017 |
November 29, 2017 |
November 29, 2017 |
November 1, 2017 |
April 26, 2018 |
|
- Beloit College
Beloit, Wisconsin, United States
|
|
| 92 |
NCT03328143 |
Recruiting |
Feasibility of Aromatherapy in an Awake Craniotomy Environment |
|
- Drug: Lavender (Lavandula angustifolia)
|
Interventional
|
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Number of consented patients
- Protocol completion
- Validation of Visual Analogue Scale for Anxiety (VAS-A)
- (and 3 more...)
|
40 |
All |
18 Years and older (Adult, Older Adult) |
NCT03328143 |
17.101 |
|
April 3, 2018 |
February 7, 2019 |
February 7, 2019 |
November 1, 2017 |
October 8, 2018 |
|
- Aurora Health Care, Aurora St. Luke's Medical Center
Milwaukee, Wisconsin, United States
|
|
| 93 |
NCT03322995 |
Recruiting |
Adaptive Modification of Neoadjuvant Therapy Based on Clinical Response in Patients With Localized Pancreatic Cancer |
|
- Drug: First-line Chemotherapy
- Drug: Second-line Chemotherapy
- Radiation: Chemoradiation
|
Interventional
|
Phase 2 |
- Medical College of Wisconsin
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The proportion of patients who are able to successfully complete all intended neoadjuvant therapy and surgery as compared to historical controls using patients who were treated with a non-adaptive neoadjuvant approach.
- The overall survival rates of patients with localized PC, treated with the adaptive neoadjuvant therapy as compared with rates historical control patients who are treated with the standard approach.
- The progression-free survival rates of patients with localized PC, treated with the adaptive neoadjuvant therapy as compared with rates historical control patients who are treated with the standard approach.
|
125 |
All |
18 Years and older (Adult, Older Adult) |
NCT03322995 |
PRO30720 |
|
June 21, 2018 |
August 1, 2022 |
August 1, 2024 |
October 26, 2017 |
July 10, 2018 |
|
- Froedtert & the Medical College of Wisconsin
Milwaukee, Wisconsin, United States
|
|
| 94 |
NCT03321916 |
Recruiting |
MacTel Laser Study |
|
- Device: 577-nm PASCAL laser
|
Interventional
|
Not Applicable |
- The Lowy Medical Research Institute Limited
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Change from baseline cone density as measured by confocal adaptive optics (AOSLO)
- Change in size of ellipsoid zone break area as measured by spectral domain optical coherence tomography (SD-OCT)
- Development or extension post therapy of areas of deficiency in cones as measured by AOSLO
|
12 |
All |
21 Years to 79 Years (Adult, Older Adult) |
NCT03321916 |
MacTelLaser1 |
|
February 8, 2018 |
December 2019 |
December 2019 |
October 26, 2017 |
August 8, 2018 |
|
- Medical College of Wisconsin & Froedtert Hospital
Milwaukee, Wisconsin, United States
|
|
| 95 |
NCT03311126 |
Recruiting |
Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma |
- Mantle Cell Lymphoma
- Non-hodgkin Lymphoma
- Non Hodgkin Lymphoma
|
- Drug: Bendamustine
- Drug: Obinutuzumab
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
- Genentech, Inc.
- National Cancer Institute (NCI)
|
Other / Industry / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression Free Survival (PFS) at 2 years
- Minimal Residual Disease (MRD) status
- Estimate the concordance rate between peripheral blood (PB) and bone marrow aspirates (BMA) in predicting MRD status.
- (and 3 more...)
|
32 |
All |
18 Years and older (Adult, Older Adult) |
NCT03311126 |
UW16086
P30CA014520
2017-0609
NCI-2017-01729 |
|
October 19, 2017 |
May 15, 2024 |
May 15, 2026 |
October 16, 2017 |
April 25, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 96 |
NCT03308669 |
Completed |
A Study of Lasmiditan in Healthy Participants When Co-administered With Topiramate |
|
- Drug: Lasmiditan
- Drug: Placebo
- Drug: Topiramate
|
Interventional
|
Phase 1 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
- Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of Lasmiditan, Topiramate, and Lasmiditan with Topiramate
- Pharmacokinetics (PK): Area Under the Concentration versus Time Curve (AUC) of Lasmiditan, Topiramate, and Lasmiditan with Topiramate
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03308669 |
16925
H8H-MC-LAHT |
|
October 16, 2017 |
December 2, 2017 |
December 2, 2017 |
October 12, 2017 |
January 30, 2018 |
|
- Covance Madison CRU
Madison, Wisconsin, United States
|
|
| 97 |
NCT03305042 |
Completed |
Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death |
- Vitamin A Deficiency
- Vitamin A Toxicity
|
|
Observational
|
|
- University of Wisconsin, Madison
- National Institute on Deafness and Other Communication Disorders (NIDCD)
|
Other / NIH |
- Observational Model: Other
- Time Perspective: Cross-Sectional
|
- Serum retinyl esters, nmol/L
- Liver vitamin A reserves, µmol/g
- Serum retinol, µmol/L
- Liver alpha-retinyl ester, nmol/g
|
27 |
All |
21 Years and older (Adult, Older Adult) |
NCT03305042 |
2015-1482 |
|
February 1, 2012 |
January 31, 2017 |
January 31, 2017 |
October 9, 2017 |
October 17, 2017 |
|
- University of Wisconsin - Madison
Madison, Wisconsin, United States
|
|
| 98 |
NCT03304002 |
Recruiting |
Implementation of a Web-based Decision Aid for Breast Cancer Surgery |
|
- Other: Breast Cancer Surgery Decision Aid
|
Observational
|
|
- University of Wisconsin, Madison
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Reach
- Acceptability
- Barriers and Facilitators to Implementation of the Decision Aid
|
116 |
All |
18 Years to 100 Years (Adult, Older Adult) |
NCT03304002 |
UWCCC-2017-0588 |
|
August 1, 2017 |
August 31, 2018 |
November 1, 2018 |
October 6, 2017 |
February 22, 2018 |
|
- University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, United States
|
|
| 99 |
NCT03302897 |
Active, not recruiting |
Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers |
|
- Biological: LEP-F1 + GLA-SE
|
Interventional
|
Phase 1 |
- IDRI
- American Leprosy Missions
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of adverse events
- Immunogenicity (IgG antibody and T cell responses to LEP-F1)
|
24 |
All |
18 Years to 55 Years (Adult) |
NCT03302897 |
IDRI-LEPVPX-118 |
|
October 2, 2017 |
January 2019 |
January 2019 |
October 5, 2017 |
January 24, 2018 |
|
- Covance Clinical Research Unit
Madison, Wisconsin, United States
|
|
| 100 |
NCT03302156 |
Recruiting |
PSMA PET and MRI in Gynecological Cancers |
|
- Drug: PSMA-based 18F-DCFPyL PET tracer
|
Interventional
|
Phase 2 |
- University of Wisconsin, Madison
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Diagnostic accuracy
- Biodistribution of PSMA
- Radiodosimetry of PSMA
- Sensitivity and specificity of PSMA-based PET/MR
|
52 |
Female |
18 Years to 99 Years (Adult, Older Adult) |
NCT03302156 |
UW17017
2017-0456 |
|
August 10, 2017 |
August 1, 2019 |
August 1, 2020 |
October 4, 2017 |
September 17, 2018 |
|
- University of Wisconsin, Madison
Madison, Wisconsin, United States
|
|
Create an RSS feed from your search for:
Download the search results for: